Eingeladene Redner:
- Prof. Dr. Annette Kopp-Schneider
Division of Biostatistics, Deutsches Krebsforschungszentrum
- Dr. Beate Presser
Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG
- Dr. Torsten Rackoll
BIH QUEST Center for Responsible Research, Charité
- Dr. Lea Vaas
Research & Pre-Clinical Statistics Group, Bayer AG
- Dr. Richardus Vonk
Oncology Statistics and Data Management, Bayer AG
Abstracts und Anmeldungen
Bitte schicken Sie Ihre Bewerbung bis zum 15.10.2023 via E-Mail an:
bernd-wolfgang.igl@boehringer-ingelheim.com oder frank.konietschke@charite.de.
Jeder Beitrag ist herzlich willkommen!
Potentielle Themen:
- Biometrie in Tierversuchen
- Statistik für toxikologische Fragestellungen
- Experimentelle Designs in der pharmazeutischen Forschung
- Statistische Analyse von Biomarkern
- Translationale Forschung
- Methodenvalidierung
- Prozess-und Stabilitätsmonitoring
- etc.
Wir freuen uns über zahlreiche Teilnahme und Beiträge, insbesondere auch von Nachwuchswissenschaftlerinnen und Nachwuchswissenschaftlern!
Time Table
| Date | Time | Presenter | Title |
|---|---|---|---|
| 16.11.2023 | 12:50 - 13:00 | Bernd-Wolfgang Igl (Boehringer Ingelheim), Frank Konietschke (Charité), Hannes-Friedrich Ulbrich (Bayer AG) | Welcome |
| 13:00 - 13:45 | Richardus Vonk (Bayer AG) | Leveraging Biomarkers for Successful Oncology Drug Development: A critical review | |
| 13:45 - 14:30 | Annette Kopp-Schneider (DKFZ) | Bayesian methods for early clinical trials | |
| 14:30 - 14:55 | Tina Lang (Bayer AG) | Good Visualizations & how to spark enthusiasm for them in a big company | |
| 14:55 - 16:15 | Tour through historic buildings, Break | ||
| 16:15 - 17:00 | Beate Presser (Boehringer Ingelheim) | Insights into the world of a CMC statistician | |
| 17:00 - 17:25 | Bernhard Schmelzer (Novartis) | Expectation ranges from over-rounded and censored data | |
| 17:25 - 17:30 | Break | ||
| 17:30 - 18:30 | All | Discussion: pre-clinical statistics – quo vadis | |
| 19:00 - ... | Dinner | ||
| 17.11.2023 | 08:15 - 09:00 | Torsten Rackoll & Daniel Schulze (Charité) | Combining everything, all at once – Considerations for preclinical meta-analysis of animal data |
| 09:00 - 09:25 | Anna Pöhlmann (Charité) | Sample size planning for rank-based multiple contrast tests | |
| 09:25 - 09:50 | Tim Litwin (University of Freiburg) | Streamlining Early Stage Experimental Design | |
| 09:50 - 10:05 | Break | ||
| 10:05 - 10:50 | Ludwig Hothorn (Leibniz University Hannover – retired) | Three 2023 news regarding ‘Statistics in in-vitro Toxicology’ | |
| 10:50 - 11:20 | Lea Vaas (Bayer AG) | The Bumpy Road to Virtual Control Groups in Toxicity Studies | |
| 11:20 - 11:45 | Alexander Gurjanov (Bayer AG) | Virtual Control Groups: Proper Selection and Performance Validation | |
| 11:45 - 11:55 | Break | ||
| 11:55 - 12:20 | Yuyue Liao (Bayer AG) | Distinguishing Capacitation Status of Sperms with CASA Parameters: An Application of Decision Tree-based Methods | |
| 12:20 - 12:45 | Jonathan Rathjens (Chrestos Concept) | On validation of micronucleus tests using historical controls | |
| 12:45 - 13:10 | Max Menssen (Leibniz University Hannover) | Prediction intervals for overdispersed Poisson data and their application to historical controls | |
| 13:10 - 13:20 | Bernd-Wolfgang Igl (Boehringer Ingelheim), Frank Konietschke (Charité), Hannes-Friedrich Ulbrich (Bayer AG) | Farewell |